Pathogenica and Life Technologies EMEA Partner to Control Hospital Acquired Infections
GLASGOW, Scotland, September 19, 2012/PRNewswire-FirstCall via African Press Organization (APO)/ — Companies to co-market Pathogenica’s HAI BioDetection Kits
through exclusive agreement in Europe, the Middle East and Africa
Life Technologies [http://www.lifetechnologies.com/us/en/home.html ] (NASDAQ: LIFE) announced an exclusive agreement with Pathogenica [http://www.pathogenica.com ], Boston, Massachusetts, to co-market and distribute for research use, the Pathogenica HAI (Hospital Acquired Infection) BioDetection Kit on the Ion Torrent PGM[TM] in Europe, the Middle East and Africa (EMEA).
Based on Pathogenica’s DxSeq[TM] technologyand the Ion Torrent[TM] sequencing platform, the kit enables identification of pathogens with high accuracy, at high specific strain resolution and at a scale that could make hospital-wide testing practical.
“Hospital acquired infections are becoming an increasingly serious health risk for patients and present significant economic issues for hospitals,” said Peter Silvester, President, Life Technologies EMEA. “The combination of Pathogenica’s technology with the Ion Torrent PGM[TM] will provide a solution that can help address this problem by enabling hospitals to quickly detect these types of infections with extreme accuracy.”
Pathogenica’s analysis software provides simple, concise output reports that indicate which species and strains are present and at what levels. These kits are not for use in the diagnosis of hospital patients.
Current methods for detecting causative organisms can take days for results or are limited to a few pathogens. The Pathogenica/Life Technologies HAI solution quickly and cost-effectively identifies not only what species are present in a sample, but also provides high-resolution sequence data that includes strain identity and resistance genes, which is critical information for understanding and containing or preventing HAI outbreaks. Pathogenica’s kit can detect more than 12 pathogenic bacteria and 15 resistance gene families in a single assay and up to 12 samples can be tested per sequencing run. Dozens of samples can simultaneously be tested in one day with results in an impressive timeframe of less than 12 hours.
The companies are evaluating an opportunity to pursue CE marking together for use of the kit as an in-vitro diagnostic assay.
“As we enter yet another market with Life Technologies as our partner, it is gratifying that together we are helping to make hospitals safer around the world,” said Yemi Adesokan, co-founder and CEO of Pathogenica. “The Ion Torrent[TM]PGM has continued to expand its installed base and is an excellent complement to our technology and our mission of making next-generation sequencing relevant and accessible to clinicians.”
Each Pathogenica kit provides reagents for identification of the following pathogens and drug resistance markers per sample: Acinetobacter baumannii, Clostridium difficile, Escherichia coli, Enterococcus faecalis, Enterococcus faecium, Enterobacter aerogenes, Enterobacter cloacae, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Coagulase negative Staph (S.epidermidis, S.saprophyticus), Staphylococcus aureus, common beta-lactamase resistance genes, mecA, and the vanA gene family. The technology allows for fast modification to incorporate the detection of emerging pathogenic fungi, viruses and resistances.
All products referenced are for Research Use Only. Not intended for diagnostic uses.
Pathogenica combines the power of Cloud-based DNA sequencing analysis and next-generation DNA sequencing to revolutionize pathogen identification and enable real-time bio-surveillance. Its DxSeq(TM) platform offers new applications in health services through rapid multiplex identification of pathogens and drug resistance genes; providing personalized diagnosis for infectious diseases that allows for more effective diagnosis and treatment of patients. Pathogenica’s high throughput pathogen identification system performs rapid and highly sensitive identification of a wide variety of biomarkers using just a common assay protocol.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today’s most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent(TM), Applied Biosystems(R), Invitrogen(TM), GIBCO(R), Ambion, Molecular Probes(R), Novex(R), and TaqMan(R). Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: http://www.lifetechnologies.com.
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Photo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO Source: Life Technologies and Pathogenica
Media Contacts: David Robertson, Leader, External Communications, Life Technologies, Email: firstname.lastname@example.org, Tel: +44-(0)141-814-5889; Matt Burke, Director of Communications, Pathogenica, Email: email@example.com, Tel: US +1-603-315-0618
Life Technologies and Pathogenica